The Janus-activated kinase-2 JAK2 is involved in the signaling of leptin and erythropoietin receptors and mediates neuroprotective effects of the hormones. In theory, JAK2 could be effective through modulation of the glutamate transporters, carriers accounting for the clearance of glutamate released during neurotransmission. The present study thus elucidated the effect of JAK2 on the glutamate transporters EAAT1, EAAT2, EAAT3 and EAAT4. To this end, cRNA encoding the carriers was injected into Xenopus oocytes with or without cRNA encoding JAK2 and glutamate transport was estimated from glutamate induced current (I glu ). I glu was observed in Xenopus oocytes expressing EAAT1 or EAAT2 or EAAT3 or EAAT4, but not in water injected oocytes. Coexpression of JAK2 resulted in an increase of I glu by 83% (EAAT1), 67% (EAAT2), 42% (EAAT3) and 126% (EAAT4). As shown for EAAT4 expressing Xenopus oocytes, the effect of JAK2 was mimicked by gain of function mutation hours. Confocal microscopy and chemiluminescence analysis revealed that JAK2 coexpression increased EAAT4 protein abundance in the cell membrane. Disruption of transcription did not appreciably modify the up-regulation of I glu in EAAT4 expressing oocytes. The decay of I glu following inhibition of carrier insertion with brefeldin A was similar in oocytes expressing EAAT4 + JAK2 and oocytes expressing EAAT4 alone, indicating that JAK2 did not appreciably affect carrier retrieval from the membrane. In conclusion, JAK2 is a novel powerful regulator of glutamate transporters and thus participates in the protection against excitotoxicity.
Introduction
Janus-activated kinase-2 JAK2 is involved in the signaling of the leptin receptor [1] . In the brain leptin influences hypothalamic neurons and thus modifies appetite and mechanisms governing energy expenditure 694 [1] . Leptin is effective through stimulation of the leptin receptor LEPRb, leading to activation of JAK2-dependent and -independent pathways. Leptin has further been shown to exert anticonvulsant activity, an effect considered to involve JAK2 and to result in part from modification of glutamate receptors [2, 3] . Excitotoxicity is further counteracted by erythropoietin, a hormone again signaling through JAK2 and interfering with glutamate signaling [4] [5] [6] .
Excitotoxicity may be modified by the efficiency of glutamate clearance from synaptic clefts, which is a function of glutamate transporters [7] [8] [9] [10] [11] . Deranged function of the glutamate transporters has been implicated in the pathophysiology of several neurodegenerative disorders such as amyotrophic lateral sclerosis, epilepsy, Huntington's disease, Alzheimer's disease and ischemic stroke injury [9] .
Little is known, however, about an influence of JAK2 on glutamate transporters. In the placenta, Leptin stimulates the system A amino acid transporter, an effect presumably involving JAK2 [12] . The present study thus explored, whether JAK2 influences the excitatory amino acid transporters EAAT1-4.
Materials and Methods

Constructs
Constructs encoding wild type human EAAT1 [13] , EAAT2 [14, 15] , EAAT3 [16, 17] and EAAT4 [18, 19] have been described previously. The JAK2 construct was generated from template human JAK2 cDNA provided by Imagenes (Berlin, Germany). Further, an inactive K882E JAK2 mutant [20] and the active V617F JAK2 mutant [21] were generated by site-directed mutagenesis (QuikChange II XL Site-Directed Mutagenesis Kit; Stratagene, Heidelberg, Germany) according to the manufacturer's instructions [22] . The following primers were used: Underlined bases indicate mutation sites. The mutants were sequenced to verify the presence of the desired mutation. The mutants were used for generation of cRNA as described previously [23] .
Voltage clamp in Xenopus oocytes
For determination of electrogenic transport, Xenopus laevis oocytes were prepared as previously described [24] .
Ten ng of wild type JAK2 cRNA were injected on the first day and 10 ng EAAT1-4 cRNA on the same day after preparation of the oocytes. All experiments were performed at room temperature 3-4 days after injections. Two-electrode voltageclamp recordings were performed at a holding potential of -60 mV. The data were filtered at 10 Hz, and recorded with a GeneClamp 500 amplifier, a DigiData 1300 A/D-D/A converter and the pClamp 9.0 software package for data acquisition and analysis (Axon Instruments, USA) [25] . The control solution (superfusate/ND96) contained 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 and 5 mM HEPES, pH 7.4 [26] . Fifty mg/l gentamycin and, where indicated, AG490 (40 µM), actinomycin D (10 µM) or brefeldin A (5 µM) were added to the solution. Glutamate was added to the solutions at the indicated concentrations. The final solutions were titrated to pH 7.4 using NaOH. The flow rate of the superfusion was 20 ml/min and a complete exchange of the bath solution was reached within about 10 s.
Immunohistochemistry and confocal microscopy
To determine EAAT4 cell surface expression by immunohistochemistry and chemiluminescence, defolliculated oocytes were first injected with 10 ng cRNA encoding either wild type JAK2 or JAK2-mutant ( V617F JAK2 or K882E JAK2) or with water and at the same day with 10 ng cRNA encoding EAAT4-HA which contains an HA epitope inserted extracellularly. After 3-4 days of injection, occytes were fixed with 4% paraformaldehyde for at least 12 h, oocytes were cryoprotected in 30% sucrose, frozen in mounting medium, and placed on a cryostat. Sections were collected at a thickness of 8 µm on coated slides and stored at -20°C. For immunostainings, sections were dehydrated at room temperature, fixated in acetone/methanol (1:1) for 15 min at room temperature, washed in PBS and pre-incubated for 1 h in 5% bovine serum albumin in PBS. The sections were incubated with primary rat anti-HA antibody for detection of EAAT4, (diluted 1:100, clone 3F10, Roche, Germany) for overnight in a moist chamber at 4°C. After washing with PBS a secondary antibody goat anti-rat FITC was used (diluted 1:1000, Cell Signaling Technology, MA, USA). The sections were mounted in prolong-gold antifad (Invitrogen). Oocytes were analyzed by a fluorescence laser scanning microscope (LSM 510, Carl Zeiss MicroImaging GmbH, Germany) with A-Plan 20x/0.48 Ph2. Brightness and contrast settings were kept constant during imaging of all oocytes in each injection series. Due to autofluorescence of the oocyte yolk, unspecific immunofluorescence was observed inside the oocyte.
Detection of EAAT4 cell surface expression by chemiluminescence
The oocytes were incubated with 0.5 µg/mL primary rat monoclonal anti-HA antibody (clone 3 F10, Roche, Mannheim, Germany) and subsequently with secondary, HRP-conjugated goat anti-rat IgG (H&L) antibody ( [27] .
Statistical analysis
Data are provided as means ± SEM, n represents the number of oocytes investigated. All experiments were repeated with at least 3 batches of oocytes; in all repetitions qualitatively similar data were obtained. Data were tested for significance using ANOVA, and results with P < 0.05 were considered statistically significant.
Results
Electrogenic glutamate transport was minimal in non-injected or water injected Xenopus laevis oocytes ( Fig. 1) . In oocytes expressing EAAT1, however, glutamate (2 mM) induced an inward current (I glu ) reflecting electrogenic entry of Na + and glutamate. I glu was significantly increased by additional injection of cRNA encoding Janus-activated kinase-2 JAK2 (Fig. 1) . The injection of JAK2 alone was not followed by the appearance of glutamate induced currents ( Fig. 1) , ruling out the theoretical possibility that the observed increase of I glu in EAAT1 expressing oocytes following additional coexpression of JAK2 was due to up-regulation of an endogenous electrogenic glutamate carrier. Thus, JAK2 enhanced EAAT1 activity.
The glutamate transporter EAAT2 similarly mediated electrogenic glutamate transport (Fig. 2) . In oocytes expressing EAAT2, glutamate (2 mM) induced an inward current (I glu ), which was again significantly enhanced by coexpression of JAK2. Electrogenic glutamate transport was further observed in oocytes expressing EAAT3 (Fig. 3) . In those oocytes glutamate (2 mM) induced an inward current (I glu ), which was again increased by coexpression of JAK2.
Glutamate further induced an inward current (I glu ) in oocytes expressing EAAT4 (Fig. 4) . I glu was in EAAT4 expressing Xenopus laevis oocytes again significantly enhanced by coexpression of JAK2. The effect of JAK2 was mimicked by the gain of function mutation V617F JAK2 but not by the inactive mutant K882E JAK2 (Fig. 4 A, B) . The effect of V617F JAK2 tended to be higher than the effect of wild type JAK2, an effect, however, not reaching statistical significance. Possibly, wild type JAK2 is not fully activated in Xenopus oocytes. Kinetic analysis of the glutamate-induced currents in EAAT4-expressing Xenopus oocytes (Fig. 4C ) yielded a maximal current of 31.8 ± 1.3 nA (n = 3). Coexpression of JAK2 significantly enhanced the maximal current to 39.6 ± 0. (p <0.05). The observation suggested that coexpression of JAK2 enhanced EAAT4 activity by increasing both, the maximal current and the affinity of the carrier.
As shown for EAAT4 expressing Xenopus oocytes, JAK2 inhibitor AG490 (40 µM) decreased the glutamate induced current. Pre-incubation of the oocytes with the JAK2 inhibitor AG490 (40 µM) reversed the stimulating effect of JAK2 expression (Fig. 5A, B) . The effect of the inhibitor was slow and reached statistical significance within 3 hours of pre-incubation with AG490.
The up-regulation of the glutamate transporters by JAK2 could have resulted in part from an increase of carrier protein abundance in the cell membrane. Immunohistochemistry and confocal microscopy together with chemiluminescence analysis was thus applied to test for altered carrier protein abundance at the cell surface.
As illustrated in Fig. 6A and Fig. 6B, JAK2 indeed significantly increased the EAAT protein abundance in the cell membrane.
At least in theory, JAK2 could enhance EAAT4 protein abundance by influencing transcription of EAAT4 or a regulator thereof. To estimate the potential contribution of altered transcription, further experiments were performed with and without actinomycin D (10 µM), an inhibitor of transcription. As a result, actinomycin D failed to significantly modify the effect of JAK2 on EAAT4 (Fig. 7A) .
The enhanced EAAT4 protein abundance in the cell membrane of JAK2 co-expressing oocytes could have resulted from accelerated insertion of new carriers into or delayed clearance of carriers from the cell membrane. To discriminate between those two possibilities the EAAT4-expressing Xenopus oocytes were treated with 5 µM Brefeldin A, which blocks the insertion of new carrier protein into the cell membrane. As shown in Fig.  7B , the glutamate induced current in the presence of Brefeldin A declined at a similar rate in oocytes expressing EAAT4 alone and in oocytes expressing EAAT4 together with JAK2. Twenty-four hours after Brefeldin A treatment EAAT4 activity was similarly low in oocytes expressing EAAT4 together with JAK2 as in oocytes expressing EAAT4 alone. This observation argues against a role of JAK2 in the carrier clearance from the cell membrane and suggests that JAK2 increases EAAT4 activity by stimulating carrier insertion into the cell membrane.
Discussion
The present observations unravel a novel regulator of glutamate transporters. The Janus-activated kinase-2 JAK2 up-regulates the activity of the four excitatory amino acid transporter isoforms EAAT1, EAAT2, EAAT3, EAAT4. The effect is at least partially due to an increase of carrier protein abundance in the cell membrane.
The effect of JAK2 could impact on the function of glutamatergic neurons and thus affect cerebral function. EAAT1 accomplishes glutamate uptake into glial cells [9] . Together with EAAT2 it is the most important carrier accounting for the clearance of glutamate released during neurotransmission [28] . The carrier is expressed mainly in astrocytes [29] [30] [31] [32] . Expression has further been reported in oligodendrocytes [33] , neurons [34, 35] , retina [36, 37] , taste buds [38] , cochlea [39, 40] , vestibular organ [41] , circumventricular organ [29] , adrenal and pineal glands [42, 43] as well as bone cells [44, 45] .
EAAT2 is similarly expressed in astrocytes [46] and similarly contributes to glutamate reuptake from the synaptic cleft [47] . Upregulation of EAAT2 activity provides neuroprotection [48] and impaired expression or activity of EAAT2 leads to extracellular glutamate accumulation and neuroexcitotoxicity [49, 50] .
EAAT3 is not only expressed in neurons [28, [51] [52] [53] [54] [55] [56] [57] , retinal ganglion cells [58] and glial cells [59, 60] but is expressed in a wide variety of nonexcitable cells and non-neuronal tissues including blood platelets [61, 62] , heart [63] , renal podocytes [64] , epididymis [65] , placenta [66, 67] and blood-brain barrier [68] .
EAAT4 is specifically expressed in cerebellar Purkinje cells and clears glutamate from the synapses connecting the climbing fibers with the Purkinje cells [54] .
Deranged function of glutamate transporters affects mainly the function of the brain. Deranged EAAT2 function has been implicated in several neurological disorders including amyotrophic lateral sclerosis (ALS) [49, 69] , Alzheimer disease [70, 71] , schizophrenia [72] , HIV associated dementia [73] , multiple sclerosis [74, 75] leukomalacia [76] , epilepsy [77, 78] , brain trauma [79] , hypoxia and stroke [80, 81] . Moreover, gene variants in EAAT2 influence reward dependence [82] . Dysfunction of EAAT3 may result in dicarboxylic aminoaciduria, which can be associated with mental retardation [83] and has been implicated in obsessive-compulsive disorder [83] , schizophrenia [72, 84, 85] , epilepsy [78] and hepatic encephalopathy [86] . EAAT4 has been associated with schizophrenia [72, 84] .
Beyond its putative role in glutamatergic transmission, JAK2 may affect glutamate transport in extracerebral tissues. JAK2 has previously been shown to participate in the regulation of cell proliferation [87, 88] . Accordingly, mutations in the gene encoding JAK2 underlie some myeloproliferative disorders [89] and JAK2 inhibitors are considered potential pharmacological candidates for the management of myelofibrosis [90, 91] .
JAK2 dependent regulation of glutamate transporters may contribute to the cerebral effects of leptin, which Kawakami protects against hypoxic neuronal injury [92] and excitotoxicity as well as seizures under a variety of conditions [2, 3, 93] . JAK2-dependent upregulation of glutamate transporters may further participate in the protective effect of erythropoeitin against excitotoxicity [6, 94] .
In conclusion, JAK2 up-regulates the glutamate transporters EAAT1, EAAT2, EAAT3 and EAAT4, an effect presumably participating in the regulation of neuronal function and survival during ischemia and in the effect of neuroprotective hormones, such as leptin and erythropoietin. 1 
